The Kentucky Opioid Abatement Advisory Commission held its second and final public hearing on the proposed use of $42 million dollars. This money would be spent over the course of six years to study the use of Ibogaine, a drug derived from plants commonly found in west Africa.
Ibogaine is currently listed as a Schedule One substance, which is a drug that is not acceptable for medical use and has a high potential for abuse. One of those testifying in the public hearing was president and chief executive officer of the Foundation for a Healthy Kentucky, Ben Chandler. He said there are still questions about the effectiveness of the drug.
